Topics referred to NICE in December 201228th January 2013
Ministers at the Department of Health have come to an agreement about the technology appraisal topics to refer to the National Institute of Health and Clinical Excellence (NICE).
NICE will handle the appraisals for the clinical and cost effectiveness of the following drugs (to treat a number of conditions including lung cancer and multiple sclerosis): afatinib, aflibercept, alemtuzumab, dimethyl fumarate, laquinimod, teriflunomide, dabrafenib, radium-223 dichloride, sipuleucel-T and ustekinumab. NICE is expected to respond to the referrals with guidance, which is usually produced within six months to two years.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.